Works matching IS 00302414 AND DT 2025 AND VI 103 AND IP 8

Results: 10

First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.

Published in:

Oncology, 2025, v. 103, n. 8, p. 742, doi. 10.1159/000542517

By:

Fujii, Yasutoshi;
Kawaoka, Tomokazu;
Shirane, Yuki;
Miura, Ryoichi;
Nakahara, Hikaru;
Yamaoka, Kenji;
Uchikawa, Shinsuke;
Fujino, Hatsue;
Ono, Atsushi;
Murakami, Eisuke;
Miki, Daiki;
Hayes, Nelson Clair;
Tsuge, Masataka;
Nakamura, Yuko;
Awai, Kazuo;
Oka, Shiro

Publication type:

Article

Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer: A Retrospective Study.

Published in:

Oncology, 2025, v. 103, n. 8, p. 699, doi. 10.1159/000543556

By:

Cui, LinHong;
Cheng, KunXiang;
Cui, MingXin;
Li, XiaoMei

Publication type:

Article

Front & Back Matter.

Published in:: Oncology, 2025, v. 103, n. 8, p. 1, doi. 10.1159/000547843
Publication type:: Article

Novel Index Based on Inflammatory Markers Correlates with Treatment Efficacy of Nivolumab for Recurrent/Metastatic Head and Neck Cancer.

Published in:

Oncology, 2025, v. 103, n. 8, p. 714, doi. 10.1159/000542683

By:

Tada, Hiroe;
Kawabata-Iwakawa, Reika;
Takahashi, Hideyuki;
Chikamatsu, Kazuaki

Publication type:

Article

Metastatic Patterns: Insights from Japanese Pathological Autopsy Registry Analysis.

Published in:

Oncology, 2025, v. 103, n. 8, p. 655, doi. 10.1159/000542684

By:

Hara, Tomohiko;
Oka, Suguru;
Ito, Shinji;
Yamaguchi, Takeshi;
Hayashida, Michikata;
Sakaguchi, Kazushige;
Urakami, Shinji

Publication type:

Article

Risk for Second Primary Ovarian Cancer: A Large Population Based on Surveillance, Epidemiology, and End Results Database.

Published in:

Oncology, 2025, v. 103, n. 8, p. 748, doi. 10.1159/000542044

By:

Hu, Haiyang;
Ren, Yangsheng;
Li, Huixing;
Zhang, Tishuo;
Sun, Lin

Publication type:

Article

Characteristics of HCC Patients with Portal Vein Thrombosis: Albumin and Survival.

Published in:

Oncology, 2025, v. 103, n. 8, p. 667, doi. 10.1159/000542774

By:

Carr, Brian;
Donghia, Rossella;
Yilmaz, Sezai

Publication type:

Article

Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution.

Published in:

Oncology, 2025, v. 103, n. 8, p. 677, doi. 10.1159/000541891

By:

Rimini, Margherita;
Foti, Silvia;
Camera, Silvia;
Rossari, Federico;
Vitiello, Francesco;
Lo Prinzi, Federica;
Aldrighetti, Luca;
De Cobelli, Francesco;
Pedica, Federica;
Arcidiacono, Paolo Giorgio;
Persano, Mara;
Cascinu, Stefano;
Casadei-Gardini, Andrea

Publication type:

Article

MUC17 Is a Potential New Prognostic Biomarker and Promotes Pancreatic Cancer Progression in Obstructive Jaundice.

Published in:

Oncology, 2025, v. 103, n. 8, p. 725, doi. 10.1159/000541874

By:

Gál, Eleonóra;
Menyhárt, István;
Veréb, Zoltán;
Kemény, Lajos;
Tiszlavicz, László;
Köhler, Zoltán Márton;
Keller-Pintér, Anikó;
Rakk, Dávid;
Szekeres, András;
Takács, Tamás;
Czakó, László;
Hegyi, Péter;
Yosef, Boshra;
Venglovecz, Viktória

Publication type:

Article

The Association between Body Mass Index and Mortality in Breast Cancer Patients Receiving Pembrolizumab.

Published in:

Oncology, 2025, v. 103, n. 8, p. 709, doi. 10.1159/000542542

By:

Chiang, Cho-Han;
Xu, Xiaocao;
Shahid, Ahmed;
Song, Junmin;
Chi, Kuan-Yu;
Chang, Yu-Cheng;
Chang, Yu;
Chiang, Cho-Hung;
Lin, Shuwen

Publication type:

Article